Limits...
IGF-IR: a new prognostic biomarker for human glioblastoma

View Article: PubMed Central - PubMed

ABSTRACT

Background:: Glioblastomas (GBMs) are the most common malignant primary brain tumours in adults and are refractory to conventional therapy, including surgical resection, radiotherapy and chemotherapy. The insulin-like growth factor (IGF) system is a complex network that includes ligands (IGFI and IGFII), receptors (IGF-IR and IGF-IIR) and high-affinity binding proteins (IGFBP-1 to IGFBP-6). Many studies have reported a role for the IGF system in the regulation of tumour cell biology. However, the role of this system remains unclear in GBMs.

Methods:: We investigate the prognostic value of both the IGF ligands' and receptors' expression in a cohort of human GBMs. Tissue microarray and image analysis were conducted to quantitatively analyse the immunohistochemical expression of these proteins in 218 human GBMs.

Results:: Both IGF-IR and IGF-IIR were overexpressed in GBMs compared with normal brain (P<10−4 and P=0.002, respectively). Moreover, with regard to standard clinical factors, IGF-IR positivity was identified as an independent prognostic factor associated with shorter survival (P=0.016) and was associated with a less favourable response to temozolomide.

Conclusions:: This study suggests that IGF-IR could be an interesting target for GBM therapy.

No MeSH data available.


Related in: MedlinePlus

Immunohistochemical expression levels of IGFI (A and B), IGFII (C and D), IGF-IR (E and F) and IGF-IIR (G and H) in glioblastomas. Original magnification × 400, scale bars=20 μm.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4559821&req=5

fig2: Immunohistochemical expression levels of IGFI (A and B), IGFII (C and D), IGF-IR (E and F) and IGF-IIR (G and H) in glioblastomas. Original magnification × 400, scale bars=20 μm.

Mentions: Quantitative evaluations of the IGFI, IGFII, IGF-IR and IGF-IIR expression levels are shown in Figure 1, and the immunohistochemical stainings are illustrated in Figure 2.


IGF-IR: a new prognostic biomarker for human glioblastoma
Immunohistochemical expression levels of IGFI (A and B), IGFII (C and D), IGF-IR (E and F) and IGF-IIR (G and H) in glioblastomas. Original magnification × 400, scale bars=20 μm.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4559821&req=5

fig2: Immunohistochemical expression levels of IGFI (A and B), IGFII (C and D), IGF-IR (E and F) and IGF-IIR (G and H) in glioblastomas. Original magnification × 400, scale bars=20 μm.
Mentions: Quantitative evaluations of the IGFI, IGFII, IGF-IR and IGF-IIR expression levels are shown in Figure 1, and the immunohistochemical stainings are illustrated in Figure 2.

View Article: PubMed Central - PubMed

ABSTRACT

Background:: Glioblastomas (GBMs) are the most common malignant primary brain tumours in adults and are refractory to conventional therapy, including surgical resection, radiotherapy and chemotherapy. The insulin-like growth factor (IGF) system is a complex network that includes ligands (IGFI and IGFII), receptors (IGF-IR and IGF-IIR) and high-affinity binding proteins (IGFBP-1 to IGFBP-6). Many studies have reported a role for the IGF system in the regulation of tumour cell biology. However, the role of this system remains unclear in GBMs.

Methods:: We investigate the prognostic value of both the IGF ligands' and receptors' expression in a cohort of human GBMs. Tissue microarray and image analysis were conducted to quantitatively analyse the immunohistochemical expression of these proteins in 218 human GBMs.

Results:: Both IGF-IR and IGF-IIR were overexpressed in GBMs compared with normal brain (P<10−4 and P=0.002, respectively). Moreover, with regard to standard clinical factors, IGF-IR positivity was identified as an independent prognostic factor associated with shorter survival (P=0.016) and was associated with a less favourable response to temozolomide.

Conclusions:: This study suggests that IGF-IR could be an interesting target for GBM therapy.

No MeSH data available.


Related in: MedlinePlus